Oxford Biomedica (LON:OXB) Releases Earnings Results

Oxford Biomedica (LON:OXB) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported GBX (30.39) earnings per share for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative net margin of 23.23% and a negative return on equity of 54.51%.

Oxford Biomedica Stock Up 3.5%

Shares of Oxford Biomedica stock traded up GBX 17 during midday trading on Friday, hitting GBX 507. The company’s stock had a trading volume of 373,239 shares, compared to its average volume of 1,100,051. The firm has a market capitalization of £613.71 million, a P/E ratio of -18.83 and a beta of 1.09. Oxford Biomedica has a 1-year low of GBX 420 and a 1-year high of GBX 952. The company has a quick ratio of 1.67, a current ratio of 2.21 and a debt-to-equity ratio of 273.08. The stock has a 50-day simple moving average of GBX 509.34 and a 200-day simple moving average of GBX 575.10.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on OXB shares. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a GBX 900 price objective on shares of Oxford Biomedica in a research note on Tuesday, September 1st. Jefferies Financial Group reiterated a “buy” rating and set a GBX 8.27 price objective on shares of Oxford Biomedica in a research note on Tuesday, June 2nd. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 595 price objective on shares of Oxford Biomedica in a report on Wednesday, September 2nd. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 580.85.

Insider Activity

In other Oxford Biomedica news, insider Roch Doliveux bought 20,250 shares of Oxford Biomedica stock in a transaction on Wednesday, September 23rd. The stock was purchased at an average cost of GBX 505 per share, for a total transaction of £102,262.50. 43.30% of the stock is owned by company insiders.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.